MedTrace Logo

Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan

NCT03200379 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150000

Last updated 2022-04-08

No results posted yet for this study

Summary

To determine the treatment efficacy, safety and long-term outcomes of chronic hepatitis C patients receiving directly acting antivirals in Taiwan

Conditions

  • Hepatitis C, Chronic

Interventions

OTHER

directly acting antivirals (DAAs)

Eligible subjects would be those CHC patients who receive approved DAA in the daily practice in Taiwan. No clinical developing medications will be allocated patients.

Sponsors & Collaborators

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    lead OTHER

Principal Investigators

  • Ming-Lung Yu, MD., PhD · HepatobiliaryDivision, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-15
Primary Completion
2037-06-15
Completion
2037-06-15

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03200379 on ClinicalTrials.gov